Sulthiame Beneficial for Symptoms of Obstructive Sleep Apnea
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 13, 2024 -- Sulthiame (STM) is beneficial for improving symptoms of obstructive sleep apnea (OSA), according to a study presented at the European Respiratory Society Congress, held from Sept. 7 to 11 in Vienna.
Jan A. Hedner, M.D., Ph.D., from Sahlgrenska Academy in Sweden, and colleagues conducted a double-blind, randomized, placebo-controlled trial involving OSA patients not accepting or tolerating continuous positive airway pressure or oral splints. Polysomnography was used to evaluate three doses of STM and placebo. Overall, 298 participants were randomly allocated to 100 mg, 200 mg, and 300 mg STM or placebo (74, 74, 75, and 75, respectively).
The researchers found that the primary efficacy end point of change in the apnea/hypopnea index during sleep associated with a ≥3 percent decrease in oxygen levels or an arousal from sleep from baseline to week 15 was met for –17.8, –34.8, and –39.9 percent, respectively, with 100 mg, 200 mg, and 300 mg STM. A placebo-adjusted, dose-dependent reduction of 47.1 percent in apnea/hypopnea with ≥4 percent oxygen desaturation was seen at week 15. Improvement in mean overnight oxygen desaturation of 0.95 and 0.87 percent was seen at week 15 for 200 mg and 300 mg STM, respectively. There was improvement in the total arousal index and sleep quality; effects on sleep macrostructure were neutral. For sleepy patients (Epworth Sleepiness Scale ≥11), the scale score was reduced.
"People taking sulthiame in the trial had a reduction in OSA symptoms such as stopping breathing during the night and feeling sleepy during the day. Their average levels of oxygen in the blood were also improved with the treatment," Hedner said in a statement.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted September 2024
Read this next
Hypoglossal Nerve Stimulator Implantation Safe for OSA in Children With Down Syndrome
FRIDAY, Aug. 15, 2025 -- For children aged younger than 13 years with Down syndrome (DS) and severe obstructive sleep apnea (OSA), hypoglossal nerve stimulator (HGNS) implantation...
Blowing Conch Shell Tied to Improved Obstructive Sleep Apnea Measures
MONDAY, Aug. 11, 2025 -- Respiratory muscle training through shankh (conch shell) blowing improves outcomes in individuals with obstructive sleep apnea (OSA), according to a study...
CPAP Preferentially Improves Cardiovascular Outcomes in High-Risk OSA
WEDNESDAY, Aug. 6, 2025 -- In patients with high-risk obstructive sleep apnea (OSA), continuous positive airway pressure (CPAP) improves cardiovascular outcomes, while harm may be...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.